Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Non-Current Assets (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Non-Current Assets data on record, last reported at $4.6 million in Q3 2022.

  • For Q3 2022, Non-Current Assets rose 731.72% year-over-year to $4.6 million; the TTM value through Sep 2022 reached $14.0 million, up 746.91%, while the annual FY2021 figure was $489000.0, 215.48% up from the prior year.
  • Non-Current Assets reached $4.6 million in Q3 2022 per AVIR's latest filing, down from $4.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.9 million in Q2 2022 and bottomed at $155000.0 in Q4 2020.
  • Average Non-Current Assets over 3 years is $1.9 million, with a median of $558000.0 recorded in 2021.
  • Peak YoY movement for Non-Current Assets: crashed 67.04% in 2021, then surged 1028.64% in 2022.
  • A 3-year view of Non-Current Assets shows it stood at $155000.0 in 2020, then skyrocketed by 215.48% to $489000.0 in 2021, then soared by 849.08% to $4.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $4.6 million in Q3 2022, $4.9 million in Q2 2022, and $4.0 million in Q1 2022.